MiNK Therapeutics Holds Annual Stockholders Meeting

MiNK Therapeutics ( (INKT) ) has shared an update.

MiNK Therapeutics held its Annual Meeting of Stockholders on June 18, 2025, where 70.41% of eligible shares were represented. During the meeting, stockholders elected Jennifer Buell and Ulf Wiinberg as Class I directors, approved an option exchange proposal, and ratified KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (INKT) stock is a Buy with a $80.00 price target. To see the full list of analyst forecasts on MiNK Therapeutics stock, see the INKT Stock Forecast page.

Spark’s Take on INKT Stock

According to Spark, TipRanks’ AI Analyst, INKT is a Underperform.

MiNK Therapeutics’ overall stock score reflects significant financial challenges and negative market sentiment. The company’s ongoing losses, reliance on external financing, and technical indicators pointing to potential downward momentum weigh heavily on the score. Despite promising clinical advancements and strategic partnerships, financial instability and valuation challenges remain primary concerns.

To see Spark’s full report on INKT stock, click here.

More about MiNK Therapeutics

Average Trading Volume: 4,664

Technical Sentiment Signal: Sell

Current Market Cap: $30.18M

Find detailed analytics on INKT stock on TipRanks’ Stock Analysis page.